Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence

Journal of Clinical Psychiatry

Volumn 74, Issue 4, 2013, Pages

  Grigoriadis, Sophie ^a,b   VonderPorten, Emily H ^a   Mamisashvili, Lana ^a   Roerecke, Michael ^a,c   Rehm, Jürgen ^a,b,c,j   Dennis, Cindy Lee ^a,b   Koren, Gideon ^a,d,e   Steiner, Meir ^b,f   Mousmanis, Patricia ^g,h,i   Cheung, Amy ^a,b   Ross, Lori E ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g Professional Development and Practice Support   (Canada)

^h York Central Hospital   (Canada)

ⁱ MARKHAM STOUFFVILLE HOSPITAL   (Canada)

^j DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CARDIOVASCULAR MALFORMATION; CHROMOSOME DISORDER; CONGENITAL HYPOTHYROIDISM; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART ATRIUM SEPTUM DEFECT; HEART MURMUR; HEART VENTRICLE SEPTUM DEFECT; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATENT DUCTUS ARTERIOSUS; PATENT FORAMEN OVALE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PULMONARY VALVE STENOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84876593338     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12r07966     Document Type: Review

References (81)

1. ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin:clinical management guidelines for obstetrician-gynecologists number 92,April 2008 (replaces practice bulletin number 87, November 2007). Use ofpsychiatric medications during pregnancy and lactation. Obstet Gynecol.2008;111(4):1001-1020.
2. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depressionduring pregnancy: a report from the American Psychiatric Association andthe American College of Obstetricians and Gynecologists. Gen HospPsychiatry. 2009;31(5):403-413
3. Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression duringpregnancy and the risk of preterm birth, low birth weight, and intrauterinegrowth restriction. Arch Gen Psychiatry. 2010;67(10):1012-1024. 10.101/archgenpsychiatry.2010.1
4. Dietz PM, Williams SB, Callaghan WM, et al. Clinically identified maternaldepression before, during, and after pregnancies ending in live births.Am J Psychiatry. 2007;164(10):1515-1520.
5. Bonari L, Koren G, Einarson TR, et al. Use of antidepressants by pregnantwomen: evaluation of perception of risk, efficacy of evidence basedcounseling and determinants of decision making. Arch Women MentHealth. 2005;8(4):214-220
6. Epidemiology study: final report on bupropion and other antidepressants, including paroxetine, in pregnancy and the occurrence of cardiovascular and major congenital malformations. GlaxoSmithKline Web site. http://www.gsk- clinicalstudyregister.com/result-detail.jsp?protocolId=113694-3&studyId= D9F4ACBC-25C0-4F26-9266-BBC8044508F5&compound=bupropion. Accessed January 29, 2013.
7. Public health advisory: paroxetine. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051731. htm Updated January 27, 2010. Accessed January 31, 2013.
8. Paxil (paroxetine) and possible increased risk of birth defects. Health Canada Web site. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/- 2005/paxil-3-pa-ap-eng.php. Updated October 7, 2005. Accessed January 31, 2013.
9. Ross LE, Grigoriadis S, Mamisashvili L, et al. Quality assessment ofobservational studies in psychiatry: an example from perinatal psychiatricresearch. Int J Methods Psychiatr Res. 2011;20(4):224-234.
10. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: A meta-analytical review of epidemiological studies. Psychol Med. 2000;30(1):89-94.
11. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates ofmajor malformations: a meta-analysis of prospective comparative studies.Pharmacoepidemiol Drug Saf. 2005;14(12):823-827.
12. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposureto serotonin reuptake inhibitors: a meta-analysis of clinical trials. ReprodToxicol. 2006;22(4):571-575
13. Kalter H. Five-decade international trends in the relation of perinatal mortalityand congenital malformations: stillbirth and neonatal death compared. Int JEpidemiol. 1991;20(1):173-179
14. Viguera AC, Cohen LS, Baldessarini RJ, et al. Managing bipolar disorderduring pregnancy: weighing the risks and benefits. Can J Psychiatry.2002;47(5):426-436.
15. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenitalmalformations: meta-analysis and consideration of potential confoundingfactors. Clin Ther. 2007;29(5):918-926.
16. Kalter H. New challenges. In: Teratology in the Twentieth Century Plus Ten.1st ed. New York, NY: Springer; 2010:53-55.
17. Adam M, Hudgins L. The importance of minor anomalies in the evaluationof the newborn. Neoreviews. 2003;4(4):e99-e104. 10.1542/neo.4-e9
18. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and theprevalence of congenital, specifically cardiac, defects: a meta-analysis ofepidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88(3):159-170
19. Gentile S. Selective serotonin reuptake inhibitor exposure during earlypregnancy and the risk of birth defects. Acta Psychiatr Scand. 2011;123(4):266-275.
20. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studiesin epidemiology: a proposal for reporting. Meta-analysis Of ObservationalStudies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008- 2012.
21. American College of Medical Genetics. Evaluation of the newborn with singleor multiple congenital anomalies New York State Department of Health Website. http://www.healthboard.com/websites/Detailed/14196.html Updated1999. Accessed December 12, 2012.
22. von Elm E, Altman DG, Egger M, et al STROBE Initiative. The Strengtheningthe Reporting of Observational Studies in Epidemiology (STROBE) statement:guidelines for reporting observational studies. Lancet.2007;370(9596): 1453-1457
23. Downs SH, Black N. The feasibility of creating a checklist for the assessment ofthe methodological quality both of randomised and non-randomised studiesof health care interventions. J Epidemiol Community Health. 1998;52(6):377-384
24. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) forassessing the quality of nonrandomized studies in meta-analyses. Departmentof Epidemiology and Community Medicine, University of Ottawa, Canada.Ottawa Hospital Research Institute Web site. http://www.ohri.ca/programs/clinical- epidemiology/oxford.htm Accessed December 12, 2012.
25. Guyatt GH, Oxman AD, Vist GE, et al GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength ofrecommendations. BMJ. 2008;336(7650):924-926
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.1986;7(3):177-188.
27. Schlesselman JJ. Case-Control Studies: Design, Conduct, Analysis. New York,NY: Oxford University Press; 1982.
28. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detectedby a simple, graphical test. BMJ. 1997;315(7109):629-634.
29. Cochran W. The combination of estimates from different experiments.Biometrics. 1954;10(1):101-129
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.Stat Med. 2002;21(11):1539-1558
31. Stata Corporation Stata Statistical Software. College Station, TX: StataCorporation; 2008.
32. Ross LE, Grigoriadis S, Mamisashvili L et al. Selected pregnancyand delivery outcomes after exposure to antidepressant medication: A systematic review and meta-analysis. JAMA Psychiatry. Published onlineahead of print February 27, 2013.
33. Moher D, Liberati A, Tetzlaff J, et al PRISMA Group. Reprint - preferredreporting items for systematic reviews and meta-analyses: the PRISMAstatement. Phys Ther. 2009;89(9):873-880.
34. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcomefollowing first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269(17):2246-2248.
35. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnantwomen taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015.
36. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternaluse of the new selective serotonin reuptake inhibitors: a prospective controlledmulticenter study. JAMA. 1998;279(8):609-610.
37. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestationalexposure to venlafaxine: a multicenter prospective controlled study. Am JPsychiatry. 2001;158(10):1728-1730.
38. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressantexposure. Am J Psychiatry. 2002;159(12):2055-2061.
39. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospectivecontrolled study to determine the safety of trazodone and nefazodone useduring pregnancy. Can J Psychiatry. 2003;48(2):106-110.
40. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of womenexposed to bupropion during pregnancy: a prospective comparative study.Am J Obstet Gynecol. 2005;192(3):932-936.
41. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotoninreuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106(6):1289- 1296.
42. Sivojelezova A, Shuhaiber S, Sarkissian L, et al. Citalopram use in pregnancy:prospective comparative evaluation of pregnancy and fetal outcome. Am JObstet Gynecol. 2005;193(6):2004-2009.
43. Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine duringpregnancy: a prospective, comparative study of birth outcomes. J ClinPsychiatry. 2006;67(8):1280-1284
44. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndromeafter in utero exposure to selective serotonin reuptake inhibitors in terminfants. Arch Pediatr Adolesc Med. 2006;160(2):173-176.
45. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors andadverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194(4):961-966.
46. Davis RL, Rubanowice D, McPhillips H, et al HMO Research Network Centerfor Education, Research in Therapeutics. Risks of congenital malformationsand perinatal events among infants exposed to antidepressant medicationsduring pregnancy. Pharmacoepidemiol Drug Saf. 2007;16(10):1086-1094.
47. Kallen BA, Otterblad Olausson P. Maternal use of selective serotoninre-uptake inhibitors in early pregnancy and infant congenital malformations.Birth Defects Res A Clin Mol Teratol. 2007;79(4):301-308.
48. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotoninreuptakeinhibitors and the risk of birth defects. N Engl J Med.2007;356(26):2675-2683.
49. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate'sclinical presentation after in utero exposure to antidepressants in latepregnancy. J Clin Psychopharmacol. 2008;28(3):334-339.
50. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetinein pregnancy: a prospective, multicentre, controlled, observational study.Br J Clin Pharmacol. 2008;66(5):695-705.
51. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenitalcardiovascular defects associated with use of paroxetine during pregnancy.Am J Psychiatry. 2008;165(6):749-752.
52. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformationsfollowing prenatal exposure to serotonin reuptake inhibitors andbenzodiazepines using population-based health data. Birth Defects Res BDev Reprod Toxicol. 2008;83(1):68-76.
53. Ramos E, St-Andre M, Rey E, et al. Duration of antidepressant use duringpregnancy and risk of major congenital malformations. Br J Psychiatry. 2008;192(5):344-350.
54. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformationsin infants following antidepressant exposure in pregnancy: results of a largeprospective cohort study. Can J Psychiatry. 2009;54(4):242-246.
55. Merlob P, Birk E, Sirota L, et al. Are selective serotonin reuptake inhibitorscardiac teratogens? echocardiographic screening of newborns with persistentheart murmur. Birth Defects Res A Clin Mol Teratol. 2009;85(10):837-841.
56. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptakeinhibitors in pregnancy and congenital malformations: population basedcohort study. BMJ. 2009;339:b3569.
57. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associatedwith selective serotonin reuptake inhibitor use during pregnancy. Mayo ClinProc. 2009;84(1):23-27.
58. Bakker MK, Kerstjens-Frederikse WS, Buys CHCM, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.Birth Defects Res A Clin Mol Teratol. 2010;88(2):94-100.
59. Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptakeinhibitors during early pregnancy and risk of congenital malformations:updated analysis. Clin Epidemiol. 2010;2:29-36.
60. Reis M, Kallen B. Delivery outcome after maternal use of antidepressantdrugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723-1733.
61. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression duringpregnancy. Can J Psychiatry. 2004;49(11):726-735.
62. Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns ofantidepressant drug use during pregnancy. Eur J Clin Pharmacol. 2006;62(10):863-870.
63. Bakker MK, Kolling P, van den Berg PB, et al. Increase in use of selectiveserotonin reuptake inhibitors in pregnancy during the last decade, apopulation-based cohort study from the Netherlands. Br J Clin Pharmacol.2008;65(4):600-606.
64. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression duringpregnancy in women who maintain or discontinue antidepressant treatment.(corrected) (published erratum appears in JAMA Jul 12;296(2) JAMA. 2006;295(5):499-507.
65. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am CollCardiol. 2002;39(12):1890-1900.
66. Hoffman JIE. Incidence of congenital heart disease 1: postnatal incidence.Pediatr Cardiol. 1995;16(3):103-113.
67. Lammers A, Hager A, Eicken A, et al. Need for closure of secundum atrialseptal defect in infancy. J Thorac Cardiovasc Surg. 2005;129(6):1353-1357.
68. Brandon AR. Ethical barriers to perinatal mental health research andevidence-based treatment: an empirical study. AJOB Primary Research.2011;2(1):2-12. 10.1080/2150716.201.561517
69. Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinicaltrials for meta-analysis. JAMA. 1999;282(11):1054-1060.
70. Mallen C, Peat G, Croft P. Quality assessment of observational studies is notcommonplace in systematic reviews. J Clin Epidemiol. 2006;59(8):765-769.
71. Kallen B, Nilsson E, Olausson PO. Antidepressant use during pregnancy:comparison of data obtained from a prescription register and from antenatalcare records. Eur J Clin Pharmacol. 2011;67(8):839-845.
72. Grzeskowiak LE, Gilbert AL, Morrison JL. Exposed or not exposed? exploringexposure classification in studies using administrative data to investigateoutcomes following medication use during pregnancy. Eur J Clin Pharmacol.2012;68(5):459-467.
73. Grigoriadis S, de Camps Meschino D, Barrons E, et al. Mood and anxietydisorders in a sample of Canadian perinatal women referred for psychiatriccare. Arch Women Ment Health. 2011;14(4):325-333
74. Hernandez-Martinez C, Val VA, Murphy M, et al. Relation between positiveand negative maternal emotional states and obstetrical outcomes. WomenHealth. 2011;51(2):124-135.
75. de Paz NC, Sanchez SE, Huaman LE, et al. Risk of placental abruption inrelation to maternal depressive, anxiety and stress symptoms. J Affect Disord.2011;130(1-2):280-284
76. Groome LJ, Swiber MJ, Bentz LS, et al. Maternal anxiety during pregnancy:effect on fetal behavior at 38 to 40 weeks of gestation. J Dev Behav Pediatr.1995;16(6):391-396.
77. Czeizel AE. Periconceptional folic acid and multivitamin SUPPLementationfor the prevention of neural tube defects and other congenital abnormalities.Birth Defects Res A Clin Mol Teratol. 2009;85(4):260-268
78. Carmichael SL, Yang W, Feldkamp ML, et al National Birth Defects PreventionStudy. Reduced risks of neural tube defects and orofacial clefts with higher dietquality. Arch Pediatr Adolesc Med. 2012;166(2):121-126
79. Pratt LA, Brody DJ. Depression and Smoking in the US Household PopulationAged 20 and Over, 2005-2008. NCHS Data Brief, No 34. Hyattsville, MD:National Center for Health Statistics; 2010.
80. Einarson A, Riordan S. Smoking in pregnancy and lactation: a review ofrisks and cessation strategies. Eur J Clin Pharmacol. 2009;65(4):325-330
81. Yonkers KA, Gotman N, Smith MV, et al. Does antidepressant use attenuatethe risk of a major depressive episode in pregnancy? Epidemiology.2011;22(6):848-854.